Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NKTR)

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

PR Newswire March 22, 2024

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

PR Newswire March 5, 2024

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

PR Newswire March 4, 2024

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

PR Newswire March 4, 2024

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

PR Newswire February 27, 2024

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

PR Newswire February 26, 2024

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire January 3, 2024

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

PR Newswire December 11, 2023

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

PR Newswire November 7, 2023
View More News ››

Opinion & Analysis (NDAQ:NKTR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NKTR)

Nektar Therapeutics Announces $30 Million Private Placement

JUST IN: $NKTR Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNektar Therapeutics Announces $30 Million...
whytestocks - March 4, 2024

WHAT’S NEXT FOR NEKTAR THERAPEUTICS?

$NKTR  Nektar Therapeutics (NASDAQ: NKTR) faced a setback with its crucial study of bempegaldesleukin in combination with...
AviseAnalytics - March 21, 2022

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$NKTR $MGNX $CTMX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650...
AviseAnalytics - January 26, 2022

watching this one for

a possible purchase in the low $21 range,was on my watchlist last spring,but its low is past and a rebound seems to be at work here,so...
coolfooldumbguy - January 15, 2020

this stock

is too expensive for me to make big bucks with no leverage,so glta.
coolfooldumbguy - March 14, 2019

possible turnaround stock

look like a good one to hold for the long term,but I will be researching it some more.
coolfooldumbguy - March 12, 2019
View more Bullboard ››

Jackpot Digital Inc.

Jackpot Digital Inc.

Jackpot Digital Inc is an electronic table game manufacturer for the cruise ship and land-based casino industry. The company ...
View More »